Cargando…
Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine
Cord blood platelet rich plasma (CB-PRP) derivatives have been investigated as potential therapeutic agents for the treatment of diverse conditions including ocular surface disease and skin ulcers. We have developed processes for the formulation of several CB-PRP preparations, which have different c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266986/ https://www.ncbi.nlm.nih.gov/pubmed/32536916 http://dx.doi.org/10.3389/fimmu.2020.00942 |
_version_ | 1783541409745207296 |
---|---|
author | Samarkanova, Dinara Cox, Steven Hernandez, Diana Rodriguez, Luciano Casaroli-Marano, Ricardo P. Madrigal, Alejandro Querol, Sergio |
author_facet | Samarkanova, Dinara Cox, Steven Hernandez, Diana Rodriguez, Luciano Casaroli-Marano, Ricardo P. Madrigal, Alejandro Querol, Sergio |
author_sort | Samarkanova, Dinara |
collection | PubMed |
description | Cord blood platelet rich plasma (CB-PRP) derivatives have been investigated as potential therapeutic agents for the treatment of diverse conditions including ocular surface disease and skin ulcers. We have developed processes for the formulation of several CB-PRP preparations, which have different composition and attributes. Here we describe the molecular characteristics of these preparations and we make recommendations as to their most appropriate clinical application based on functional and immunomodulatory profiles. We show that incubation of adult peripheral blood mononuclear cells (PBMCs) with all three preparations dramatically reduced the production of INFγ and the expression of NKG2D and CD107a in NK, NKT, and T cells thus diminishing their activation, we propose that the likely mechanism is the high levels of soluble NKG2D ligands present in plasma. Of the three preparations we investigated, CB platelet lysate (PL) and platelet releaseate (PR) have higher concentrations of trophic and pro-angiogenic factors, CB platelet poor plasma (PPP) has the lowest concentration of all analytes measured. Based on these finding we propose that CB-PR is the most suitable raw material for skin wound patches, while CB-PL and PPP can be used to prepare eye drops for severe ocular surface pathologies and inflammatory conditions such as corneal ulcers or severe dry eye disease, respectively. |
format | Online Article Text |
id | pubmed-7266986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72669862020-06-12 Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine Samarkanova, Dinara Cox, Steven Hernandez, Diana Rodriguez, Luciano Casaroli-Marano, Ricardo P. Madrigal, Alejandro Querol, Sergio Front Immunol Immunology Cord blood platelet rich plasma (CB-PRP) derivatives have been investigated as potential therapeutic agents for the treatment of diverse conditions including ocular surface disease and skin ulcers. We have developed processes for the formulation of several CB-PRP preparations, which have different composition and attributes. Here we describe the molecular characteristics of these preparations and we make recommendations as to their most appropriate clinical application based on functional and immunomodulatory profiles. We show that incubation of adult peripheral blood mononuclear cells (PBMCs) with all three preparations dramatically reduced the production of INFγ and the expression of NKG2D and CD107a in NK, NKT, and T cells thus diminishing their activation, we propose that the likely mechanism is the high levels of soluble NKG2D ligands present in plasma. Of the three preparations we investigated, CB platelet lysate (PL) and platelet releaseate (PR) have higher concentrations of trophic and pro-angiogenic factors, CB platelet poor plasma (PPP) has the lowest concentration of all analytes measured. Based on these finding we propose that CB-PR is the most suitable raw material for skin wound patches, while CB-PL and PPP can be used to prepare eye drops for severe ocular surface pathologies and inflammatory conditions such as corneal ulcers or severe dry eye disease, respectively. Frontiers Media S.A. 2020-05-27 /pmc/articles/PMC7266986/ /pubmed/32536916 http://dx.doi.org/10.3389/fimmu.2020.00942 Text en Copyright © 2020 Samarkanova, Cox, Hernandez, Rodriguez, Casaroli-Marano, Madrigal and Querol. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Samarkanova, Dinara Cox, Steven Hernandez, Diana Rodriguez, Luciano Casaroli-Marano, Ricardo P. Madrigal, Alejandro Querol, Sergio Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine |
title | Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine |
title_full | Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine |
title_fullStr | Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine |
title_full_unstemmed | Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine |
title_short | Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine |
title_sort | cord blood platelet rich plasma derivatives for clinical applications in non-transfusion medicine |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266986/ https://www.ncbi.nlm.nih.gov/pubmed/32536916 http://dx.doi.org/10.3389/fimmu.2020.00942 |
work_keys_str_mv | AT samarkanovadinara cordbloodplateletrichplasmaderivativesforclinicalapplicationsinnontransfusionmedicine AT coxsteven cordbloodplateletrichplasmaderivativesforclinicalapplicationsinnontransfusionmedicine AT hernandezdiana cordbloodplateletrichplasmaderivativesforclinicalapplicationsinnontransfusionmedicine AT rodriguezluciano cordbloodplateletrichplasmaderivativesforclinicalapplicationsinnontransfusionmedicine AT casarolimaranoricardop cordbloodplateletrichplasmaderivativesforclinicalapplicationsinnontransfusionmedicine AT madrigalalejandro cordbloodplateletrichplasmaderivativesforclinicalapplicationsinnontransfusionmedicine AT querolsergio cordbloodplateletrichplasmaderivativesforclinicalapplicationsinnontransfusionmedicine |